2022 Global CRSwNP Awareness Day
Wednesday, 20 April 2022
On Wednesday, 20 April 2022 EUFOREA will celebrate the launch of the very first Global Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Awareness Day in Brussels.
Until now, patients with CRSwNP have had only limited opportunities for their voices to be heard, hence missing the opportunity to contribute to the improvement of CRSwNP care. In 2021, the Patient Advisory Board of EUFOREA published a statement that offered novel insights on the underestimated burden of CRSwNP and shortcomings of current care as well as multiple recommendations for action plans for implementation of better care for CRSwNP among all physicians treating patients with this disabling disease.
The aims of this campaign are:
- to raise awareness of CRSwNP and comorbidities (asthma, atopic dermatitis, and its impact on quality of life among physicians, and policymakers),
- to encourage healthcare professionals at all levels to learn more about how they can improve outcomes for patients living with CRSwNP through improved diagnosis, treatment, and referrals to specialist care,
- to educate patients on the symptoms of CRSwNP so that they can seek appropriate care in the management of their disease or to support loved ones suffering from CRSwNP and associated comorbidities including Asthma, Atopic Dermatitis (Eczema, and Allergy - respiratory or food allergy).
Mark your calendars, by clicking the below button, for this monumental event and #LetsTalkCRS !
Patients Unmet Needs in Chronic Rhinosinusitis with Nasal Polyps Care
The background of this article focuses on European patients with chronic rhinosinusitis with nasal polyps (CRSwNP) that have had only limited occasions to unite to have their voices heard, hence missing the opportunity to contribute to the improvement of CRSwNP care.
Uncontrolled Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Biologics
Uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) is the most bothersome phenotype of chronic rhinosinusitis, as is typically characterized by a type 2 inflammatory reaction and by comorbidities, including asthma, nonsteroidal anti-inflammatory drug–exacerbated respiratory disease and allergies.
Main Sponsor
Co-Sponsor
Corporate Sponsor
Non-Profit Supporters
